54
Participants
Start Date
October 16, 2020
Primary Completion Date
March 24, 2022
Study Completion Date
March 24, 2022
AT-1501
AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Hospital for Special Surgery (HSS), New York
Johns Hopkins University Medical Center, Baltimore
Augusta University, Augusta
University of Indiana, Indianapolis
The University of Kansas Medical Center, Kansas City
Texas Neurology, P.A., Dallas
Houston Methodist Neurological Institute, Houston
Barrows Neurological Institute, Phoenix
University of California Irvine, Orange
California Pacific Medical Center, San Francisco
Providence Brain & Spine Institute, Portland
Massachusetts General Hospital, Boston
Montreal Neurological Institute and Hospital, Montreal
Lead Sponsor
Anelixis Therapeutics, LLC
INDUSTRY